Loading...

ITRM ITERUM THERAPEUTICS PLC Capital Structure Changes 8-K Filing

TRM

TRM

ITERUM THERAPEUTICS PLC

(ITRM)

2024 8-K

Delisting Notice

Financial Results Announced

Fundraising Announcement

AGM Results Summary

Listing Non-Compliance

New Product Launch

Financial Statements

Management Changes

Debt Restructuring

Financial Statements

Equity Offerings

Board Appointments

Director Resignation

Financial Results

Nasdaq Compliance

Q3 Financial Results

Milestone Payment Deferral

Nasdaq Compliance

Share Issuance Approval

Nasdaq Delisting Notice

Q2 Financial Results

Expiration of Rights Offeri...

Rights Offering

Annual General Meeting

Appointment, Compliance, FD...

Financial Results Announcement

Resignation of Chief Medica...

Resubmission of New Drug Ap...

Delisting Notice

Financial Results Announcement

Business Update

Shareholder Vote on Issuanc...

Phase 3 Clinical Trial Results

Resignation of Director

Compliance regained with Na...

Earnings Reports

Clinical Trial Enrollment C...

Earnings Reports

Extraordinary General Meeting

Earnings Reports

Constitution Amendment and ...

Earnings Reports

Annual General Meeting Anno...

External Links:

Iterum Therapeutics agreed to defer a $20 million milestone payment to Pfizer for FDA approval of its drug ORLYNVAH until October 2026, with an 8% interest rate on the deferred amount.

AI Assistant

ITERUM THERAPEUTICS PLC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.